| Caressa Gullikson, Dc Llc | |
|
108 E Hersey St Ste 2a, Ashland, OR 97520-1363 | |
| (541) 482-4823 | |
| Not Available |
| Full Name | Caressa Gullikson, Dc Llc |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 108 E Hersey St Ste 2a, Ashland, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003487232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| 261Q00000X | Clinic/center | (* (Not Available)) | Secondary |
| Provider Name | Caressa A Gullikson |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1780048694 PECOS PAC ID: 5991099236 Enrollment ID: I20160809000747 |
News Archive
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
Citizen-generated data could help combat the misuse of medicines and prevent antimicrobial resistance (AMR), says a report by the Global Partnership for Sustainable Development Data (GPSDD).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).
Pancreatic ductal adenocarcinoma is an almost uniformly fatal disease regardless of the stage at time of diagnosis. However, a small percentage of patients develop a form of ductal adenocarcinoma associated with cystic lesions that can be detected earlier, is less aggressive and has a 50 percent long-term survival rate.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caressa Gullikson, Dc Llc 108 E Hersey St Ste 2a, Ashland, OR 97520-1363 Ph: (541) 482-4823 | Caressa Gullikson, Dc Llc 108 E Hersey St Ste 2a, Ashland, OR 97520-1363 Ph: (541) 482-4823 |
News Archive
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
Citizen-generated data could help combat the misuse of medicines and prevent antimicrobial resistance (AMR), says a report by the Global Partnership for Sustainable Development Data (GPSDD).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).
Pancreatic ductal adenocarcinoma is an almost uniformly fatal disease regardless of the stage at time of diagnosis. However, a small percentage of patients develop a form of ductal adenocarcinoma associated with cystic lesions that can be detected earlier, is less aggressive and has a 50 percent long-term survival rate.
› Verified 3 days ago
Dr. Ilene Karen Rubinstein, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 854 A St, Ashland, OR 97520 Phone: 541-488-0688 Fax: 541-488-0644 | |
Matthew Norman Terreri, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 240 E Hersey St Ste 0, Ashland, OR 97520 Phone: 541-482-0625 Fax: 541-482-3364 | |
Dr. Robert Medeck, DC CCST Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 1875 Hwy 99 N, Ste 11, Ashland, OR 97520 Phone: 541-482-2225 Fax: 541-488-2962 | |
Kathleen F Manley, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1745 Ashland St, Ashland, OR 97520 Phone: 541-482-3362 Fax: 541-482-3362 | |
Dr. Susan Demarinis, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 376 B St, Ashland, OR 97520 Phone: 541-482-0999 Fax: 541-482-0999 | |
Pj Kolker Llc Dba The Blue Giraffe Day Spa Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 51 Water St, Ashland, OR 97520 Phone: 541-488-3335 Fax: 541-488-3337 |